The end of the year always seems very busy.

Chen Huaiqing did not need to handle specific matters, but Chen Huaiqing had to make a decision on some matters.

For example, the Motta Group's dividend distribution.

Motta Group naturally had a pretty good life last year.

The total revenue of the entire group's main business, motorcycles and automobiles, reached more than 110 billion.

These two items alone brought Motta Group a net profit of 17.6 billion.

In addition to the vehicle business, such as engines, in addition to personal use, it is also sold to external parties.

Changan Automobile, Sichuan Automobile, Jialin and Jianshe Construction are all customers of Mota Power.

They can buy all the latest engines from Mota Power.

In fact, for them, if their own R&D capabilities are not good enough, buying an engine from Mota Power is a good thing.

Other domestic manufacturers also come to Mota Power to purchase engines.

1.2 million motorcycle engines and 90,000 car engines were sold for delivery.

In addition, there are other miscellaneous incomes, such as Motta Agriculture, etc. The total revenue of Motta Group reached 146 billion.

This does not include some companies in which Motta Group has a stake.

For example, Mota-based companies such as Mota Semiconductor, Mota Microelectronics, and Mota Aircraft.

As well as companies like Xiangjiang Yuantao, Xiangjiang Yuantao has never turned over profits to the Mota Group headquarters.

In the financial report, Motta Group's net profit is not too high, because R&D investment continues to rise.

The market is used to Motta Group spending money on research and development.

Therefore, everyone no longer pays much attention to the net profit of the Motta Group, but pays more attention to the revenue of the Motta Group.

Compared with the financial reports released to the public, the report Chen Huaiqing read at this time contained more detailed and accurate information.

“It looks like the second machine tool can be profitable!”

The sales volume of the second machine tool has increased a lot.

Not only domestic sales, but also internationally, Second Machine Tool has gradually begun to sell some machine tool products.

Although from an international perspective, the products sold by Second Machine Tool are only top-notch machine tool products.

But it can't stand and has a very high selling price advantage.

Only by constantly letting products enter the market can we know what the market is like.

If a company does not work hard in the market, it will definitely not work.

Only in the market can we understand the market and know the direction of our efforts.

Just working hard is not enough.

You have to work hard in the right direction and work hard in the wrong direction. The more you work, the more serious the mistake will be.

Personally, Chen Huaiqing doesn't care whether the second machine tool is profitable or not.

What he cares more about is the continuous technological breakthroughs of the second machine tool.

Machine tools are the foundation of a country's equipment manufacturing and are known as the mother of manufacturing. Its technical level represents a country's comprehensive competitiveness.

How will China's machine tool technology level be ranked globally?

I can definitely say that it is definitely at the forefront.

Globally, there are not many countries that can manufacture their own machine tools.

Of course, with China's machine tool technology level at this time, if you want to be in the top ten, you will definitely not be able to do so.

Chen Huaiqing has enough patience in the development of the second machine tool. It is only 1992 now. It will take another 20 years to do it. A small progress will be made every year. After 20 years, it will be a big step forward.

Song Qi was sitting on Chen Huaiqing's desk with a water glass in his hand. There was black tea in the water glass.

Drinks for women recommended by the Murtagh Institute of Biology and Medicine.

The scope of research at the Murtagh Institute of Biology and Medicine is quite broad.

Under the Murtagh Institute of Biology and Medicine, there are many various research institutes, including life sciences, Chinese patent medicine, Western medicine and other research.

This research institute is affiliated to Motta Biopharmaceutical Group Co., Ltd.

In addition to Murtagh Biomedical Research Institute, Murtagh Biomedical Group also has Murtagh Hospital, pharmaceutical companies and medical device companies.

Although Murtagh Biopharmaceutical Group has the name Murtagh, it has nothing to do with Murtagh Group in a legal sense.

If I insist on saying so, it is that the major shareholder of both companies is Miduo Investment.

Mito Investment is the absolute controlling shareholder of Mota Biopharmaceutical Group. In addition to Mito Investment, Shuchuan State-owned Assets and Pension Fund Company also have shares.

Motta Biopharmaceutical Group has invested quite a lot in the research and development of new drugs and medical devices.

Basic medical equipment, such as infusion tubes, medical gloves, masks, and surgical instruments, are all produced.

Nowadays, these things are quite expensive in China.

Yes, it is quite expensive.

Motta Hospital is a large consumer in these areas, and domestic production is insufficient, so it can only invest its own money.

In addition to providing these basic medical equipment, the most important thing of Motta Medical Equipment Company is the development and production of monitors, ventilators, blood cell analyzers, urine analyzers, ultrasound machines, line machines, etc.

Anyway, whatever is lacking now, Mota Medical Instruments will research on it.

For example, Motta Medical Equipment Company is also developing artificial lungs.

Nuclear magnetic resonance instruments are also being developed.

This thing is expensive!

One unit costs tens of millions, and it cannot be shut down. If it is shut down and restarted, it will cost hundreds of thousands.

Anyway, it’s an expensive word.

The nuclear magnetic resonance instrument has not been around for a long time abroad. It only started to be used in 1973.

Therefore, it is only a gap of more than ten years. There is a gap, but it is not big.

NMR is very important for diagnosis.

Compared with the talent and experience of traditional Chinese medicine doctors, what is modern medicine?

Train doctors in a streamlined and standardized manner.

It means that doctors can become workers on the production line. Through various instruments, all the body data of the whole person can be displayed in front of doctors. Doctors no longer make medical diagnoses based on experience, but rely on various tests.

Data forms the entire medical activity into a standardized process.

Is this good?

The biggest advantage is that most diseases can be treated quickly and easily.

There are standardized treatment procedures out there.

As for difficult and complicated diseases...

There is nothing ordinary doctors can do.

You don’t need to go to an ordinary doctor for treatment, you can go to a higher-level hospital.

"I don't care about profits anymore, as long as I don't continue to expand losses."

Chen Huaiqing said with a smile: "You have to have confidence in our R&D personnel. As long as we rise up in technology, won't making money be a matter of minutes?"

Second Machine Tool's remuneration to its employees is naturally extremely good, and it has the largest number of R&D personnel among domestic machine tool companies.

Of course, no matter how good the salary is, it is still low compared to that of foreign machine tool companies.

Less than one-fifth of that.

The low labor cost naturally makes the cost of the entire second machine tool much lower.

Lower cost than others is a huge competitive advantage.
Chapter completed!